Luspatercept — Discount Pricing
Luspatercept is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Luspatercept Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $181.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Luspatercept
Luspatercept is a prescription medication. Ask your doctor if Luspatercept is right for you.
How to Check Luspatercept Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Luspatercept at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Blood Disorders
About Luspatercept
Luspatercept is an important medication used to treat specific types of anemia. As a specialty drug, its cost can be a significant concern for patients. At TheDrugClub, we're dedicated to helping our members access the medications they need at more affordable prices, including potential savings on luspatercept.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Luspatercept is approved for (FDA label)
REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions ( 1.1 ). • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions ( 1.2 ). • Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) ( 1.3 ).
Source: Read the full FDA label on DailyMed. Label effective date: February 27, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Luspatercept (FDA label)
• For injection: 25 mg white to off-white lyophilized powder in a single-dose vial for reconstitution. • For injection: 75 mg white to off-white lyophilized powder in a single-dose vial for reconstitution. • For injection: 25 mg lyophilized powder in a single-dose vial for reconstitution ( 3 ). • For injection: 75 mg lyophilized powder in a single-dose vial for reconstitution ( 3 ).
Source: FDA prescribing information (DailyMed). Set ID: 82f4d266-3f52-41eb-86ba-0abf3cf468e8. SPL document ID: 769ec39a-61bd-4726-b14a-9594897baa67. Label effective date: February 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Luspatercept (FDA label)
The following clinically significant adverse reactions are described elsewhere in the labeling: • Thrombosis/Thromboembolism [see Warnings and Precautions ( 5.1 )] • Hypertension [see Warnings and Precautions ( 5.2 )] • Extramedullary Hematopoietic Masses [see Warnings and Precautions ( 5.3 )] The most common (>10%) adverse reactions were fatigue, headache, musculoskeletal pain, arthralgia, dizziness/vertigo, nausea, diarrhea, cough, abdominal pain, dyspnea, COVID-19, edema peripheral, hypertension, and hypersensitivity ( 6.1 ).
Source: FDA prescribing information (DailyMed). Set ID: 82f4d266-3f52-41eb-86ba-0abf3cf468e8. SPL document ID: 769ec39a-61bd-4726-b14a-9594897baa67. Label effective date: February 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Luspatercept (FDA label)
None. None ( 4 ).
Source: FDA prescribing information (DailyMed). Set ID: 82f4d266-3f52-41eb-86ba-0abf3cf468e8. SPL document ID: 769ec39a-61bd-4726-b14a-9594897baa67. Label effective date: February 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Luspatercept (FDA label)
• Thrombosis/Thromboembolism: Increased risk in patients with beta thalassemia. Monitor patients for signs and symptoms of thromboembolic events and institute treatment promptly ( 5.1 ). • Hypertension: Monitor blood pressure (BP) during treatment. Initiate anti-hypertensive treatment if necessary ( 5.2 ). • Extramedullary Hematopoietic (EMH) Masses: Increased risk in patients with beta thalassemia. Monitor patients for symptoms and signs or complications resulting from the EMH masses. Treat according to clinical guidelines and discontinue treatment in case of serious complications due to EMH masses ( 5.3 ). • Embryo-Fetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception ( 5.4 , 8.1 , 8.3 ). 5.1 Thrombosis/Thromboembolism In adult patients with beta thalassemia, thromboembolic events (TEE) were reported in 8/223 (3.6%) REBLOZYL-treated patients. Reported TEEs included deep vein thromboses, pulmonary embolus, portal vein thrombosis, and ischemic strokes.
Source: FDA prescribing information (DailyMed). Set ID: 82f4d266-3f52-41eb-86ba-0abf3cf468e8. SPL document ID: 769ec39a-61bd-4726-b14a-9594897baa67. Label effective date: February 27, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.